MedTrace Logo

Positron Emission Tomography (PET) During Radio-chemotherapy to Treat Otorhinolaryngological Cancer

NCT02469922 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2021-07-27

No results posted yet for this study

Summary

Open multicentric study assessing predictive value of 18-FDG PET (SUV max) at 20 Gy during radio-chemotherapy, on the loco-regional control after 2 years

Conditions

  • Malignant Neoplasm of Head and Neck
  • Locally Advanced Malignant Neoplasm

Interventions

DEVICE

Positron emission tomography

RADIATION

radiochemotherapy

Every patients will be treated with radiochemotherapy as a standard of care

Sponsors & Collaborators

  • Center Eugene Marquis

    lead OTHER

Principal Investigators

  • Castelli Joël, Doctor · Centre de Lutte Contre le Cancer Centre Eugène Marquis

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2021-01-29
Completion
2021-01-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02469922 on ClinicalTrials.gov